Overview of immune response during SARS-CoV-2 infection: lessons from the past

VK Shah, P Firmal, A Alam, D Ganguly… - Frontiers in …, 2020 - frontiersin.org
After the 1918 flu pandemic, the world is again facing a similar situation. However, the
advancement in medical science has made it possible to identify that the novel infectious …

[HTML][HTML] Molecular immune pathogenesis and diagnosis of COVID-19

X Li, M Geng, Y Peng, L Meng, S Lu - Journal of pharmaceutical analysis, 2020 - Elsevier
Abstract Coronavirus disease 2019 (COVID-19) is a kind of viral pneumonia which is caused
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergence of …

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

CJ Gordon, EP Tchesnokov, E Woolner… - Journal of Biological …, 2020 - ASBMB
Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control
this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS …

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

E De Wit, F Feldmann, J Cronin… - Proceedings of the …, 2020 - National Acad Sciences
The continued emergence of Middle East Respiratory Syndrome (MERS) cases with a high
case fatality rate stresses the need for the availability of effective antiviral treatments …

Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence

Y Cao, Q Deng, S Dai - Travel medicine and infectious disease, 2020 - Elsevier
The novel coronavirus infection that initially found at the end of 2019 has attracted great
attention. So far, the number of infectious cases has increased globally to more than 100 …

Two years into the COVID-19 pandemic: lessons learned

SJR da Silva, JCF do Nascimento… - ACS infectious …, 2022 - ACS Publications
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible
and virulent human-infecting coronavirus that emerged in late December 2019 in Wuhan …

Recent discovery and development of inhibitors targeting coronaviruses

T Pillaiyar, S Meenakshisundaram, M Manickam - Drug discovery today, 2020 - Elsevier
Human coronaviruses (CoVs) are enveloped viruses with a positive-sense single-stranded
RNA genome. Currently, six human CoVs have been reported including human coronavirus …

The drug repurposing for COVID-19 clinical trials provide very effective therapeutic combinations: lessons learned from major clinical studies

C Chakraborty, AR Sharma, M Bhattacharya… - Frontiers in …, 2021 - frontiersin.org
SARS-CoV-2 has spread across the globe in no time. In the beginning, people suffered due
to the absence of efficacious drugs required to treat severely ill patients. Nevertheless, still …

Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities

R Cannalire, C Cerchia, AR Beccari… - Journal of medicinal …, 2020 - ACS Publications
The newly emerged coronavirus, called SARS-CoV-2, is the causing pathogen of pandemic
COVID-19. The identification of drugs to treat COVID-19 and other coronavirus diseases is …

Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019

A Barlow, KM Landolf, B Barlow… - … : The Journal of …, 2020 - Wiley Online Library
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has
evolved into an emergent global pandemic. Coronavirus disease 2019 (COVID‐19) can …